Furthermore, in vitro experiments using a panel of breast cancer cell lines confirmed an overexpression of TrkA and phospho-TrkA in HER2-positive cell lines and demonstrated that targeting phospho-TrkA signaling, using the Trk inhibitor GNF-5837, resulted in decreased cell viability. This evidence concerns the gene ERBB2 and breast cancer.